A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma

Table 1

Clinical characteristics of patients in TCGA-LUAD internal training set and validation set.

Characteristics	Train ()	Test ()	Total ()	value	FDR
Age
Median [min-max]	66.00 [33.00, 88.00]	66.00 [41.00, 86.00]	66.00 [33.00, 88.00]
Gender				1	1
Female	162 (36.40%)	81 (18.20%)	243 (54.61%)
Male	134 (30.11%)	68 (15.28%)	202 (45.39%)
Stage				0.43	1
Stage I	157 (35.28%)	87 (19.55%)	244 (54.83%)
Stage II	68 (15.28%)	36 (8.09%)	104 (23.37%)
Stage III	54 (12.13%)	21 (4.72%)	75 (16.85%)
Stage IV	17 (3.82%)	5 (1.12%)	22 (4.94%)
T				0.88	1
T1	108 (24.27%)	49 (11.01%)	157 (35.28%)
T2	152 (34.16%)	80 (17.98%)	232 (52.13%)
T3	24 (5.39%)	14 (3.15%)	38 (8.54%)
T4	12 (2.70%)	6 (1.35%)	18 (4.04%)
M				0.52	1
M0	198 (44.49%)	100 (22.47%)	298 (66.97%)
M1	17 (3.82%)	5 (1.12%)	22 (4.94%)
MX	81 (18.20%)	44 (9.89%)	125 (28.09%)
N				0.19	0.93
N0	186 (41.80%)	105 (23.60%)	291 (65.39%)
N1	54 (12.13%)	27 (6.07%)	81 (18.20%)
N2	49 (11.01%)	17 (3.82%)	66 (14.83%)
N3	2 (0.45%)	0 (0.0+0%)	2 (0.45%)
NX	5 (1.12%)	0 (0.0+0%)	5 (1.12%)